Recombinant lymphotoxin alpha derivative - Shanghai Fudan-Zhangjiang

Drug Profile

Recombinant lymphotoxin alpha derivative - Shanghai Fudan-Zhangjiang

Alternative Names: rhLT; rhLT28-171; rhLTα-Da

Latest Information Update: 26 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  • Class Antihyperglycaemics; Antineoplastics; Antivirals; Cytokines; Lymphokines; Tumour necrosis factors
  • Mechanism of Action Tumour necrosis factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Oesophageal cancer

Most Recent Events

  • 28 Mar 2011 Phase-II clinical trials in Oesophageal cancer in China (IV)
  • 30 Sep 2007 Phase-I clinical trials in Solid tumours in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top